Skip to main content

Table 1 Baseline characteristics of bromocriptine treated patients and matched controls †

From: Incidence of heart valve disease in women treated with the ergot-derived dopamine agonist bromocriptine

Variable Bromocriptine (n = 3035) Controls (n = 15,175) p-value
Age at onset (year) 31.7 [27.8, 36.8] 31.7 [27.7, 36.8] -
Comorbidities, n (%)    
Ischemic heart disease 20 (0.7) 64 (0.4) 0.11
Acute myocardial infarction 5 (0.2) 20 (0.1) 0.86
Atrial fibrillation 8 (0.3) 27 (0.2) 0.45
Ischemic stroke 15 (0.5) 50 (0.3) 0.22
Transient ischemic attack 7 (0.2) 19 (0.1) 0.25
Embolism 0 (0.0) 9 (0.1) 0.37
Pulmonary embolism 4 (0.1) 15 (0.1) 0.84
Deep vein thrombosis 16 (0.5) 39 (0.3) 0.02
Atherosclerosis 6 (0.2) 15 (0.1) 0.24
Coagulopathy 5 (0.2) 26 (0.2) 1.0
Hypertension 75 (2.5) 220 (1.4) 0.0001
Diabetes 42 (1.4) 101 (0.7) 0.0001
Diagnosis of alcohol misuse 53 (1.7) 123 (0.8) 0.0001
Chronic obstructive lung disease 21 (0.7) 42 (0.3) 0.0007
Malignancy 37 (1.2) 178 (1.2) 0.90
Chronic renal disease 16 (0.5) 52 (0.3) 0.17
Abnormal liver function 14 (0.5) 58 (0.4) 0.64
Medication, n (%)    
Beta-blockers 82 (2.7) 247 (1.6) 0.0001
Calcium channel blockers 38 (1.3) 132 (0.9) 0.06
RAS inhibitors 38 (1.3) 164 (1.1) 0.47
Vasodilators 0(0.0) 0 (0.0) 1.0
Antiadrenergic drugs 8 (0.3) 8 (0.1) 0.001
Thiazides 84 (2.8) 270 (1.8) 0.0004
Loop diuretics 57 (1.9) 117 (0.8) 0.0001
Spironolactone 11 (0.4) 14 (0.1) 0.0007
Diuretics, combination 12 (0.4) 49 (0.3) 0.65
Digoxin 6 (0.2) 27 (0.2) 1.0
Statins 18 (0.6) 74 (0.5) 0.54
Antidiabetics 55 (1.8) 107 (0.7) 0.0001
Aspirin 33 (1.1) 108 (0.7) 0.04
ADP inhibitors 0 (0.0) 0 (0.0) 1.0
Anticoagulants 5 (0.2) 23 (0.2) 1.0
  1. patients and controls were matched for age and sex
  2. p-values were obtained by chi-square test for comparison between patients and controls
  3. IQR Interquartile range
  4. Pharmaceuticals: Claimed prescription within 366 days before baseline date
  5. RAS Renin-Angiotensin system